NM49 is a multi-specific antibody identified through Numab™s proprietary discovery and engineering technology platform designed to activate tumor associated macrophage phagocytosis Numab to receive...
Numab Therapeutics Announces First Patient Dosed in Phase 1 Multiple Ascending Dose (MAD) Study of NM26 for Moderate to Severe Atopic Dermatitis
HORGEN, Switzerland--(BUSINESS WIRE)--Numab Therapeutics AG (Numab), a clinical stage biotechnology company advancing a proprietary pipeline of immunology and oncology therapeutics, announced today that the first subject has been dosed in the Phase 1 clinical study of NM26-2198, a first-in-class bi-specific antibody for the treatment of moderate-to-severe atopic dermatitis (AD).
Numab Therapeutics has dosed the first subject in a Phase I clinical trial of NM26-2198, a bi-specific antibody to treat moderate-to-severe atopic dermatitis (AD).
WÄDENSWIL, Switzerland--(BUSINESS WIRE)--Numab Therapeutics AG (“Numab”) and Ono Pharmaceutical Co., Ltd. (“Ono”) today announced that Ono has exercised its option to enter into a development and license agreement for a multispecific antibody candidate that was generated through a research collaboration between the two companies initiated in 2017. Under the terms of the license agreement, Ono acquires intellectual property rights and exclusive global development and commercialization rights for a multispecific antibody targeting a novel immuno-oncology target. In consideration for the discovery work and the license, Numab will receive up to CHF 258 million in research funding, upfront and milestone payments plus tiered single to double digit royalties on future sales.
WÄDENSWIL, Switzerland, SHENYANG, China, & SHANGHAI--(BUSINESS WIRE)--Numab Therapeutics AG (Numab) and 3SBio Inc. (“3SBio”, HKEX:1530) announced today that 3SBio’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) exercised its option for an exclusive regional license for the development and commercialization of NM28, a potential best-in-class bivalent mesothelin (MSLN)-targeting CD3 T cell engager.
Numab Therapeutics has raised CHF 100 million ($111 million) to expand clinical development of its lead PD-L1x4-1BB drug candidate into multiple cancer indications. Novo Ventures and HBM Partners co-lead the series C round with assists from investors on both sides of the Atlantic.
COPENHAGEN, Denmark, May 20, 2021 /PRNewswire/ -- Novo Holdings today announced that it has co-led the oversubscribed CHF 100 million (approximately USD 110 million) Series C financing in Numab Therapeutics AG (Numab) alongside HBM Partners, with participation from new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., fund and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors.
WAEDENSWIL, Switzerland--(BUSINESS WIRE)--Numab Therapeutics AG, a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation, today announced the closing of a CHF 100 million (approximately USD 110 million) Series C financing. The financing was co-led by new investors Novo Holdings and HBM Partners, with participation from additional new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., funds and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors. Concurrent with the financing, Nanna Lüneborg from Novo Ventures, Matthias Fehr from HBM Partners, and Carlo Incerti from Forbion have been appointed to Numab’s Board of Directors.
Numab Therapeutics has raised CHF 100 million ($111 million) to expand clinical development of its lead PD-L1x4-1BB drug candidate into multiple cancer indications. Novo Ventures and HBM Partners co-lead the series C round with assists from investors on both sides of the Atlantic.